Unmet Needs in TAVR: Conduction Disturbances and Management of Coronary Artery Disease.
Vincent AuffretCarine RidardNadia SalernoSabato SorrentinoPublished in: Journal of clinical medicine (2022)
Over the past two decades, transcatheter aortic valve replacement (TAVR) swiftly evolved from a disrupting technology towards mainstream therapy in the field of severe symptomatic aortic stenosis. A series of randomized evaluations established its role in treating severe aortic stenosis patients across all surgical risk categories, paving the way for an extension of its indications to younger low-risk patients with a longer life expectancy. Therefore, managing comorbidities and limiting procedural complications, which may affect long-term outcomes, is of paramount importance. Among those, new-onset conduction disturbances and concomitant coronary artery disease remain two of the most debated issues. In the present review, we will discuss the incidence, prognostic impact, and unmet needs of patients with post-TAVR new-onset conduction disturbances and the ongoing challenges posed by the management of concomitant coronary artery disease.
Keyphrases
- aortic stenosis
- coronary artery disease
- transcatheter aortic valve replacement
- ejection fraction
- aortic valve replacement
- transcatheter aortic valve implantation
- aortic valve
- cardiovascular events
- coronary artery bypass grafting
- percutaneous coronary intervention
- end stage renal disease
- newly diagnosed
- left ventricular
- chronic kidney disease
- early onset
- risk factors
- prognostic factors
- peritoneal dialysis
- type diabetes
- clinical trial
- heart failure
- open label
- placebo controlled
- phase iii
- randomized controlled trial
- phase ii
- patient reported
- cell therapy